Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Serum amyloid A

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    125 result(s) found for: Serum amyloid A. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2015-002603-29 Sponsor Protocol Number: ALN-TTRSC-005 Start Date*: 2015-12-01
    Sponsor Name:Alnylam Pharmaceuticals, Inc
    Full Title: An Open-Label Study To Evaluate The Efficacy And Safety Of Revusiran In Patients With Transthyretin-Mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post Orthotopic Liver Trans...
    Medical condition: Transthyretin (TTR)-mediated Familial Amyloidotic Polyneuropathy (FAP)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10019889 Hereditary neuropathic amyloidosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) PT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004670-10 Sponsor Protocol Number: AG10-333 Start Date*: 2020-07-07
    Sponsor Name:Eidos Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial)
    Medical condition: Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) FR (Completed) BG (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000467-24 Sponsor Protocol Number: ALN-TTR02-002 Start Date*: 2012-05-08
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients with TTR Amyl...
    Medical condition: Transthyretin mediated amyloidosis (ATTR)
    Disease: Version SOC Term Classification Code Term Level
    15.1 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    15.1 10010331 - Congenital, familial and genetic disorders 10019889 Hereditary neuropathic amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) PT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002098-23 Sponsor Protocol Number: ALN-TTRSC02-002 Start Date*: 2019-05-09
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
    Medical condition: Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10019889 Hereditary neuropathic amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) BG (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) GR (Completed) NL (Trial now transitioned) CY (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001644-65 Sponsor Protocol Number: ALN-TTR02-003 Start Date*: 2013-07-19
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who ...
    Medical condition: Transthyretin mediated amyloidosis (ATTR)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    14.1 10010331 - Congenital, familial and genetic disorders 10019889 Hereditary neuropathic amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001698-10 Sponsor Protocol Number: ION-682884-CS3 Start Date*: 2020-03-06
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    Medical condition: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PT (Completed) DE (Completed) ES (Ongoing) IT (Completed) SE (Completed) GR (Prematurely Ended) FR (Completed) CY (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001557-27 Sponsor Protocol Number: A9951024 Start Date*: 2014-01-13
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED TRIALTO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF PF-04360365 (PONEZUMAB) IN ADULT SUBJECTS WITH PROBABLE CEREBRAL A...
    Medical condition: Cerebral Amyloid Angiopathy (CAA)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10068044 Cerebral amyloid angiopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001427-40 Sponsor Protocol Number: ION-682884-CS13 Start Date*: 2022-06-07
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    Medical condition: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) CY (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005384-16 Sponsor Protocol Number: FLORAMICAR Start Date*: 2016-04-26
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: A prospective single-arm, monocentric, phase-II explorative study on evaluation of diagnostic use of the PET tracer (18F)-florbetaben (Neuraceq®) in patient with patient with suspected cardiac amyl...
    Medical condition: Patients with high clinical suspicion of cardiac amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013030-25 Sponsor Protocol Number: GE-067-007 Start Date*: 2010-05-12
    Sponsor Name:GE Healthcare Ltd. and its Affiliates
    Full Title: A Principal Open-Label Study to Compare the Brain Uptake of [18F]flutemetamol with Brain Amyloid Levels Determined Post-Mortem
    Medical condition: The subjects have a short life expectancy. GE-067-007 will determine the level of association between brain uptake of (18F)flutemetamol and brain amyloid levels. Assessments will be based on analy...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048669 Terminal state LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002465-35 Sponsor Protocol Number: B3461028 Start Date*: 2014-04-07
    Sponsor Name:FoldRx Pharmaceuticals, a Pfizer Company
    Full Title: A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826)...
    Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) SE (Completed) CZ (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000686-40 Sponsor Protocol Number: pulsar Start Date*: 2023-05-04
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis
    Medical condition: cardiac amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004739-58 Sponsor Protocol Number: BAN2401-G000-301 Start Date*: 2019-06-12
    Sponsor Name:Eisai Limited
    Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease
    Medical condition: Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    20.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018714-73 Sponsor Protocol Number: GE-067-010 CPR Start Date*: 2010-04-26
    Sponsor Name:GE Healthcare Ltd. and its Affiliates
    Full Title: A Principal, Open-Label, Single Center Study to Validate the Detection of Cerebral Cortical Amyloid with Flutemetamol (18F) Injection in Subjects Previously Biopsied
    Medical condition: Patients who have been biopsied during an intracranial procedure due to suspected Normal Pressure Hydrocephalus (NPH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029773 Normal pressure hydrocephalus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2016-000868-42 Sponsor Protocol Number: B3461045 Start Date*: 2016-09-26
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYR...
    Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) CZ (Completed) DE (Completed) SE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005542-38 Sponsor Protocol Number: MK-8931-019 Start Date*: 2014-03-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    Full Title: A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment...
    Medical condition: prodromal Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) DE (Completed) GB (Prematurely Ended) FI (Completed) NL (Prematurely Ended) BE (Completed) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004280-32 Sponsor Protocol Number: AG10-301 Start Date*: 2019-05-10
    Sponsor Name:Eidos Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)
    Medical condition: Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) PT (Completed) ES (Ongoing) NL (Completed) BE (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005236-25 Sponsor Protocol Number: Dox/Urso Start Date*: 2011-12-21
    Sponsor Name:Umeå University
    Full Title: A phase II multicenter pilot study of the safety and efficacy of Doxycycline/UrsoDeoxyCholicAcid on disease progression in ATTR amyloidosis
    Medical condition: Transthyretin amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10019893 Hereditary neuropathic amyloidosis, Swedish type LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004776-56 Sponsor Protocol Number: AT1-2017 Start Date*: 2019-03-06
    Sponsor Name:Arctic Therapeutics ehf
    Full Title: Phase IIa Biomarker Study to Evaluate the Efficacy, Safety and Tolerability of AT-1 in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) - the AT1-HCCAA study
    Medical condition: Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018715-15 Sponsor Protocol Number: GE-067-011 Start Date*: 2010-05-12
    Sponsor Name:GE Healthcare Ltd. and its Affiliates
    Full Title: A principal, prospective, open-label biopsy study to validate detection of cerebral cortical amyloid with Flutemetamol (18F) Injection in NPH subjects
    Medical condition: Subjects who are scheduled for intracranial pressure measurement or intracranial shunt placement due to suspected Normal Pressure Hydrocephalus (NPH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029773 Normal pressure hydrocephalus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 21:15:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA